Cargando…

Usefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and Substantia Nigra Hyperechogenicity as Additional Diagnostic Markers for Distinguishing between Parkinson’s Disease and Atypical Parkinsonian Syndromes

BACKGROUND: We aimed to evaluate the utility of the combined use of cardiac (123)I-metaiodobenzylguanidine (MIBG) scintigraphy, olfactory testing, and substantia nigra (SN) hyperechogenicity on transcranial sonography (TCS) in differentiating Parkinson’s disease (PD) from atypical parkinsonian syndr...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujita, Hiroaki, Suzuki, Keisuke, Numao, Ayaka, Watanabe, Yuji, Uchiyama, Tomoyuki, Miyamoto, Tomoyuki, Miyamoto, Masayuki, Hirata, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094741/
https://www.ncbi.nlm.nih.gov/pubmed/27812167
http://dx.doi.org/10.1371/journal.pone.0165869
_version_ 1782465164201689088
author Fujita, Hiroaki
Suzuki, Keisuke
Numao, Ayaka
Watanabe, Yuji
Uchiyama, Tomoyuki
Miyamoto, Tomoyuki
Miyamoto, Masayuki
Hirata, Koichi
author_facet Fujita, Hiroaki
Suzuki, Keisuke
Numao, Ayaka
Watanabe, Yuji
Uchiyama, Tomoyuki
Miyamoto, Tomoyuki
Miyamoto, Masayuki
Hirata, Koichi
author_sort Fujita, Hiroaki
collection PubMed
description BACKGROUND: We aimed to evaluate the utility of the combined use of cardiac (123)I-metaiodobenzylguanidine (MIBG) scintigraphy, olfactory testing, and substantia nigra (SN) hyperechogenicity on transcranial sonography (TCS) in differentiating Parkinson’s disease (PD) from atypical parkinsonian syndromes (APSs), such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). METHODS: Cardiac MIBG scintigraphy, card-type odor identification testing (Open Essence (OE), Wako, Japan), and TCS were performed with 101 patients with PD and 38 patients with APSs (MSA and PSP). Receiver operating characteristic (ROC) curve analysis was used to assess the sensitivity and specificity of these batteries for diagnosing PD from APSs. The diagnostic accuracy of the three tests was also assessed among patients at the early disease stage (drug-naïve patients with a disease duration of 3 years or less). RESULTS: In differentiating PD from APSs, the area under the ROC curve was 0.74 (95% CI, 0.65–0.83), 0.8 (95% CI, 0.73–0.87), and 0.75 (95% CI, 0.67–0.82) for TCS, cardiac MIBG scintigraphy, and olfactory testing, respectively. The diagnostic sensitivity and specificity were 53.1% and 91.7%, respectively, for TCS, 70.3% and 86.8%, respectively, for cardiac MIBG scintigraphy, 58.4% and 76.3%, respectively, for OE. Among early-stage patients, sensitivity and specificity were 50.0% and 93.8%, respectively, for TCS, 57.1% and 87.5%, respectively, for cardiac MIBG scintigraphy, and 54.8% and 79.2%, respectively, for OE. At least one positive result from 3 tests improved sensitivity (86.1%) but decreased specificity (63.2%). In contrast, at least 2 positive results from 3 tests had good discrimination for both early-stage patients (50.0% sensitivity and 93.8% specificity) and patients overall (57.8% sensitivity and 95.8% specificity). Positive results for all 3 tests yielded 100% specificity but low sensitivity (25%). CONCLUSIONS: At least 2 positive results from among TCS, cardiac MIBG scintigraphy, and olfactory testing can support clinical diagnosis in distinguishing PD from APSs.
format Online
Article
Text
id pubmed-5094741
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-50947412016-11-18 Usefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and Substantia Nigra Hyperechogenicity as Additional Diagnostic Markers for Distinguishing between Parkinson’s Disease and Atypical Parkinsonian Syndromes Fujita, Hiroaki Suzuki, Keisuke Numao, Ayaka Watanabe, Yuji Uchiyama, Tomoyuki Miyamoto, Tomoyuki Miyamoto, Masayuki Hirata, Koichi PLoS One Research Article BACKGROUND: We aimed to evaluate the utility of the combined use of cardiac (123)I-metaiodobenzylguanidine (MIBG) scintigraphy, olfactory testing, and substantia nigra (SN) hyperechogenicity on transcranial sonography (TCS) in differentiating Parkinson’s disease (PD) from atypical parkinsonian syndromes (APSs), such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). METHODS: Cardiac MIBG scintigraphy, card-type odor identification testing (Open Essence (OE), Wako, Japan), and TCS were performed with 101 patients with PD and 38 patients with APSs (MSA and PSP). Receiver operating characteristic (ROC) curve analysis was used to assess the sensitivity and specificity of these batteries for diagnosing PD from APSs. The diagnostic accuracy of the three tests was also assessed among patients at the early disease stage (drug-naïve patients with a disease duration of 3 years or less). RESULTS: In differentiating PD from APSs, the area under the ROC curve was 0.74 (95% CI, 0.65–0.83), 0.8 (95% CI, 0.73–0.87), and 0.75 (95% CI, 0.67–0.82) for TCS, cardiac MIBG scintigraphy, and olfactory testing, respectively. The diagnostic sensitivity and specificity were 53.1% and 91.7%, respectively, for TCS, 70.3% and 86.8%, respectively, for cardiac MIBG scintigraphy, 58.4% and 76.3%, respectively, for OE. Among early-stage patients, sensitivity and specificity were 50.0% and 93.8%, respectively, for TCS, 57.1% and 87.5%, respectively, for cardiac MIBG scintigraphy, and 54.8% and 79.2%, respectively, for OE. At least one positive result from 3 tests improved sensitivity (86.1%) but decreased specificity (63.2%). In contrast, at least 2 positive results from 3 tests had good discrimination for both early-stage patients (50.0% sensitivity and 93.8% specificity) and patients overall (57.8% sensitivity and 95.8% specificity). Positive results for all 3 tests yielded 100% specificity but low sensitivity (25%). CONCLUSIONS: At least 2 positive results from among TCS, cardiac MIBG scintigraphy, and olfactory testing can support clinical diagnosis in distinguishing PD from APSs. Public Library of Science 2016-11-03 /pmc/articles/PMC5094741/ /pubmed/27812167 http://dx.doi.org/10.1371/journal.pone.0165869 Text en © 2016 Fujita et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Fujita, Hiroaki
Suzuki, Keisuke
Numao, Ayaka
Watanabe, Yuji
Uchiyama, Tomoyuki
Miyamoto, Tomoyuki
Miyamoto, Masayuki
Hirata, Koichi
Usefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and Substantia Nigra Hyperechogenicity as Additional Diagnostic Markers for Distinguishing between Parkinson’s Disease and Atypical Parkinsonian Syndromes
title Usefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and Substantia Nigra Hyperechogenicity as Additional Diagnostic Markers for Distinguishing between Parkinson’s Disease and Atypical Parkinsonian Syndromes
title_full Usefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and Substantia Nigra Hyperechogenicity as Additional Diagnostic Markers for Distinguishing between Parkinson’s Disease and Atypical Parkinsonian Syndromes
title_fullStr Usefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and Substantia Nigra Hyperechogenicity as Additional Diagnostic Markers for Distinguishing between Parkinson’s Disease and Atypical Parkinsonian Syndromes
title_full_unstemmed Usefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and Substantia Nigra Hyperechogenicity as Additional Diagnostic Markers for Distinguishing between Parkinson’s Disease and Atypical Parkinsonian Syndromes
title_short Usefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and Substantia Nigra Hyperechogenicity as Additional Diagnostic Markers for Distinguishing between Parkinson’s Disease and Atypical Parkinsonian Syndromes
title_sort usefulness of cardiac mibg scintigraphy, olfactory testing and substantia nigra hyperechogenicity as additional diagnostic markers for distinguishing between parkinson’s disease and atypical parkinsonian syndromes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094741/
https://www.ncbi.nlm.nih.gov/pubmed/27812167
http://dx.doi.org/10.1371/journal.pone.0165869
work_keys_str_mv AT fujitahiroaki usefulnessofcardiacmibgscintigraphyolfactorytestingandsubstantianigrahyperechogenicityasadditionaldiagnosticmarkersfordistinguishingbetweenparkinsonsdiseaseandatypicalparkinsoniansyndromes
AT suzukikeisuke usefulnessofcardiacmibgscintigraphyolfactorytestingandsubstantianigrahyperechogenicityasadditionaldiagnosticmarkersfordistinguishingbetweenparkinsonsdiseaseandatypicalparkinsoniansyndromes
AT numaoayaka usefulnessofcardiacmibgscintigraphyolfactorytestingandsubstantianigrahyperechogenicityasadditionaldiagnosticmarkersfordistinguishingbetweenparkinsonsdiseaseandatypicalparkinsoniansyndromes
AT watanabeyuji usefulnessofcardiacmibgscintigraphyolfactorytestingandsubstantianigrahyperechogenicityasadditionaldiagnosticmarkersfordistinguishingbetweenparkinsonsdiseaseandatypicalparkinsoniansyndromes
AT uchiyamatomoyuki usefulnessofcardiacmibgscintigraphyolfactorytestingandsubstantianigrahyperechogenicityasadditionaldiagnosticmarkersfordistinguishingbetweenparkinsonsdiseaseandatypicalparkinsoniansyndromes
AT miyamototomoyuki usefulnessofcardiacmibgscintigraphyolfactorytestingandsubstantianigrahyperechogenicityasadditionaldiagnosticmarkersfordistinguishingbetweenparkinsonsdiseaseandatypicalparkinsoniansyndromes
AT miyamotomasayuki usefulnessofcardiacmibgscintigraphyolfactorytestingandsubstantianigrahyperechogenicityasadditionaldiagnosticmarkersfordistinguishingbetweenparkinsonsdiseaseandatypicalparkinsoniansyndromes
AT hiratakoichi usefulnessofcardiacmibgscintigraphyolfactorytestingandsubstantianigrahyperechogenicityasadditionaldiagnosticmarkersfordistinguishingbetweenparkinsonsdiseaseandatypicalparkinsoniansyndromes